
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics Inc exhibits a positive outlook due to the demonstrated efficacy of its product candidate, lorundrostat, which has shown a placebo-adjusted blood pressure reduction exceeding 10 mmHg, a significant threshold that is likely to enhance prescriber interest. The robust and differentiated profile of lorundrostat in treating uncontrolled and resistant hypertension is emphasized by favorable results that stand out against Phase 3 competitor data, indicating a strong market potential. Furthermore, the anticipated near-term FDA feedback and the upcoming New Drug Application (NDA) submission add to the optimism surrounding the company's future prospects.
Bears say
Mineralys Therapeutics faces several fundamental challenges that contribute to a negative outlook on its stock. The risks identified include the potential failure of its product candidate, lorundrostat, to meet peak commercial revenue estimates due to limitations in market size, penetration rates, and pricing strategies. Additionally, the company may encounter difficulties in securing the necessary capital to fund ongoing operations and face hurdles related to the continued development and commercialization of its therapeutic programs.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares